Cognitive Bias Modification for Thought-Action Fusion

Status Completed

Clinical Trial Summary

An important cognitive bias in many emotional disorders, particularly obsessive-compulsive disorder (OCD), is thought-action fusion (TAF). TAF describes the bias to interpret the presence of unwanted mental intrusions as morally equivalent to acting on them (TAF-M), and/or increasing the likelihood of the feared consequence occurring to either oneself (TAF-LS) or others (TAF-LO). The present study is designed to test the feasibility of a single session computerized cognitive bias modification for interpretations (CBM-I) to reduce TAF among individuals who reported obsessional intrusions. Participants will be randomized to (a) the TAF-incongruent condition (TAF-INC), designed to decrease TAF linked to obsessional thoughts, to (b) the TAF-congruent condition (TAF-CON), designed to render TAF-like interpretation of obsessional thoughts unchallenged, or to (c) a Stress Management Psychoeducation (SMP) condition, designed to provide information about stress reduction, but not target TAF directly.

Clinical Trial Description

Individuals who display at least mild obsessional and TAF symptoms will be invited to the current study. Participants will be randomized to one of the three interpretation training conditions: an TAF-INC, TAF-CON, or SMP. Before and after the training, participants will complete some self-report questionnaires and clinician administered measures. The computerized training will provide statements intended to activate the mechanisms involved in thought-action-fusion (TAF), which will almost always produce a negative outcome interpretation. It is hypothesized that through TAF-INC participants will learn alternative, more neutral, ways of interpreting the thoughts and lower the subject's TAF. The TAF-CON condition will receive the same statements as TAF-INC, but TAF-CON is designed to leave the interpretation of the scenarios unchallenged. The study will also include another comparison condition, SMP, to test if TAF-INC outperforms not only TAF-CON, but also stress reduction techniques provided in empirically supported psychological treatment. The SMP training will be similar in procedure and structure to the other two conditions, but it will provide psychoeducation about stress and stress management techniques. ;

Study Design

Related Conditions & MeSH terms

Obsessive-Compulsive Disorder

Clinical Trial Details

NCT number	NCT03921255
Study type	Interventional
Source	University of Wisconsin, Milwaukee
Contact
Status	Completed
Phase	N/A
Start date	April 10, 2016
Completion date	December 31, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04934007` - Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder	N/A
Recruiting	`NCT04071990` - Family Involvement in CBGT of OCD: a Randomized Controlled Trial	N/A
Completed	`NCT02541968` - Internet-based vs Face-to-face Cognitive Behavioural Therapy for Obsessive-compulsive Disorder	N/A
Recruiting	`NCT05651295` - A Precision Medicine Approach to Target Engagement for Emotion Regulation	N/A
Recruiting	`NCT05391503` - Light Therapy for Obsessive-compulsive Disorder (OCD)	N/A
Recruiting	`NCT04539951` - Pragmatic Trial of Obsessive-compulsive Disorder	Phase 2
Completed	`NCT03416504` - Methods for Managing Intrusive Thoughts	N/A
Not yet recruiting	`NCT06029738` - Effect on Obsessive-Compulsive Beliefs and Symptoms of MCT-OCD	N/A
Recruiting	`NCT02844049` - European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS	N/A
Completed	`NCT02911324` - Cannabinoid Medication for Adults With OCD	Phase 1/Phase 2
Terminated	`NCT02909660` - What Are You Looking for? Psychometric and Experimental Analyses of Reassurance Seeking in Obsessive-compulsive Disorder	N/A
Terminated	`NCT02234011` - A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder	Phase 2
Completed	`NCT02217995` - Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients	N/A
Withdrawn	`NCT01953042` - Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders	N/A
Completed	`NCT02655926` - Deep Brain Stimulation for Severe Obsessive Compulsive Disorder	N/A
Completed	`NCT04919785` - Deep Brain Stimulation in Severe Obsessive-compulsive Disorder	N/A
Completed	`NCT00742664` - Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project	Phase 1/Phase 2
Terminated	`NCT00758966` - Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder	Phase 2
Completed	`NCT00523718` - Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder	Phase 2
Completed	`NCT00074815` - Treatment of Obsessive Compulsive Disorder in Children	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Cognitive Bias Modification for Thought-Action Fusion — TAF

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms